371 related articles for article (PubMed ID: 37936700)
1. Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imaging.
Cohn DE; Forder A; Marshall EA; Vucic EA; Stewart GL; Noureddine K; Lockwood WW; MacAulay CE; Guillaud M; Lam WL
Front Immunol; 2023; 14():1275890. PubMed ID: 37936700
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment signaling and therapeutics in cancer progression.
Goenka A; Khan F; Verma B; Sinha P; Dmello CC; Jogalekar MP; Gangadaran P; Ahn BC
Cancer Commun (Lond); 2023 May; 43(5):525-561. PubMed ID: 37005490
[TBL] [Abstract][Full Text] [Related]
3. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types.
Ptacek J; Locke D; Finck R; Cvijic ME; Li Z; Tarolli JG; Aksoy M; Sigal Y; Zhang Y; Newgren M; Finn J
Lab Invest; 2020 Aug; 100(8):1111-1123. PubMed ID: 32203152
[TBL] [Abstract][Full Text] [Related]
6. [Characterization of the tumor microenvironment by highly multiplexed microscopy].
Schürch CM
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):21-24. PubMed ID: 36222923
[TBL] [Abstract][Full Text] [Related]
7. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
8. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
[TBL] [Abstract][Full Text] [Related]
10. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.
Parra ER; Zhai J; Tamegnon A; Zhou N; Pandurengan RK; Barreto C; Jiang M; Rice DC; Creasy C; Vaporciyan AA; Hofstetter WL; Tsao AS; Wistuba II; Sepesi B; Haymaker C
Sci Rep; 2021 Feb; 11(1):4530. PubMed ID: 33633208
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment.
Johnson AM; Boland JM; Wrobel J; Klezcko EK; Weiser-Evans M; Hopp K; Heasley L; Clambey ET; Jordan K; Nemenoff RA; Schenk EL
J Thorac Oncol; 2021 Oct; 16(10):1694-1704. PubMed ID: 34048945
[TBL] [Abstract][Full Text] [Related]
12. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
[TBL] [Abstract][Full Text] [Related]
13. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint.
Verma NK; Wong BHS; Poh ZS; Udayakumar A; Verma R; Goh RKJ; Duggan SP; Shelat VG; Chandy KG; Grigoropoulos NF
EBioMedicine; 2022 Sep; 83():104216. PubMed ID: 35986950
[TBL] [Abstract][Full Text] [Related]
14. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
[TBL] [Abstract][Full Text] [Related]
15. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
16. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma.
Mi H; Ho WJ; Yarchoan M; Popel AS
Front Immunol; 2022; 13():892250. PubMed ID: 35634309
[TBL] [Abstract][Full Text] [Related]
17. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
19. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
Buoncervello M; Gabriele L; Toschi E
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
